2,3-Di-tert-Butyl-chinoxalin | 20587-90-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2,3-Di-tert-Butyl-chinoxalin
• 英文别名: 2,3-Di-tert-butylquinoxaline；2,3-ditert-butylquinoxaline
• CAS: 20587-90-0
• 化学式: C₁₆H₂₂N₂
• 分子量: 242.364
• InChiKey: ISAIOVSPOCYJEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• CATALYST FOR CROSS-COUPLING REACTION, AND PROCESS FOR PRODUCTION OF AROMATIC COMPOUND USING THE SAME
  申请人：Nakamura Masaharu

  公开号：US20110152523A1

  公开（公告）日：2011-06-23

  The present invention provides a process for efficiently producing an alkylated aromatic compound in good yield, by a cross-coupling reaction between an alkyl halide and an aromatic magnesium reagent. A process for producing an aromatic compound represented by Formula (1): R—Ar′  (1) wherein R is a hydrocarbon group, and Ar′ is an aryl group; the process comprising: reacting a compound represented by Formula (2): R—X  (2) wherein X is a halogen atom, and R is as defined above, with a magnesium reagent represented by Formula (3): Ar′—MgY  (3) wherein Y is a halogen atom, and Ar′ is as defined above, in the presence of a catalyst for cross-coupling reactions comprising an iron compound and a bisphosphine compound represented by Formula (4): wherein Q is a divalent group derived from an aromatic ring by removing two hydrogen (H) atoms on adjacent carbon atoms; and each Ar is independently an aryl group.

  本发明提供了一种高效产生烷基芳香化合物的方法，通过烷基卤化物和芳香镁试剂之间的交叉偶联反应，以良好的产率产生烷基芳香化合物的方法，所述方法包括：将由式（2）表示的化合物：R—X（2）其中X是卤素原子，R如上所定义，与由式（3）表示的镁试剂：Ar′—MgY（3）其中Y是卤素原子，Ar′如上所定义，在交叉偶联反应的催化剂存在下反应，所述催化剂包括一种铁化合物和一种由式（4）表示的双膦化合物：其中Q是通过去除相邻碳原子上的两个氢（H）原子从芳香环中衍生的二价基团；每个Ar都是独立的芳基团。
• ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME
  申请人：YEN FENG-WEN

  公开号：US20200190065A1

  公开（公告）日：2020-06-18

  The present invention discloses an organic compound and an organic electroluminescence device using the organic compound as an emitting host material, an electron transfer material or a hole blocking material in the light emitting layer of the organic electroluminescence device. The organic compound may be for increasing a half-life or current efficiency of the organic electroluminescence device, and may be for lowering a driving voltage or power consumption of the organic electroluminescence device. The same definition as described in the present invention.

  本发明公开了一种有机化合物，以及使用该有机化合物作为有机电致发光器件中发射主体材料、电子传输材料或阻挡孔的材料的有机电致发光器件。该有机化合物可以用于提高有机电致发光器件的半衰期或电流效率，并且可以用于降低有机电致发光器件的驱动电压或功耗。与本发明中描述的相同定义。
• Melanocortin-4 receptor binding compounds and methods of use thereof
  申请人：Vos Tricia J.

  公开号：US20080269217A1

  公开（公告）日：2008-10-30

  Provided are MC4-R binding compounds of the formula XVII: wherein L 2 is a linker group, and P 1 , P 2 , P 3 , P 4 , Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , t, s, and R are as described in the specification. Methods of using the compounds to treat MC4-R associated disorders, such as disorders associated with weight loss, are also provided.

  提供的是公式XVII的MC4-R结合化合物： 其中L2是连接基团，而P1，P2，P3，P4，Z1，Z2，Z3，Z4，Z5，t，s和R如规范所述。还提供了使用这些化合物治疗MC4-R相关疾病的方法，例如与体重减轻相关的疾病。
• Inhibitors of AKT Activity
  申请人：Chen Chixu

  公开号：US20090062327A1

  公开（公告）日：2009-03-05

  The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

  本发明提供了抑制Akt活性的化合物。特别地，所披露的化合物选择性地抑制一种或两种Akt亚型。本发明还提供了包含这种抑制剂化合物的组合物以及通过向需要癌症治疗的患者施用该化合物来抑制Akt活性的方法。
• Inhibitors of Akt Activity
  申请人：Cosford D.P. Nicholas

  公开号：US20080009507A1

  公开（公告）日：2008-01-10

  The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.

  本发明提供了抑制Akt活性的化合物。具体而言，所披露的化合物选择性地抑制一种或两种Akt同工型。本发明还提供了包含这种抑制化合物的组合物以及通过向需要癌症治疗的患者施用该化合物来抑制Akt活性的方法。